Dr. Amy Egan, MD, MPH
Dr. Amy Egan, MD, MPH
Principal, Amy G Egan Consulting LLC
Master of Public Health, Johns Hopkins Bloomberg School of Public Health
Dr. Amy Egan has over 15 years of experience in FDA Drug Safety and Regulatory Oversight. She earned her BS in Biology from Santa Clara University, her MD from Loyola University Stritch School of Medicine, and her MPH from Johns Hopkins Bloomberg School of Public Health. She completed her internship and residency in Internal Medicine at Evanston Northwestern Healthcare. Today, this expert is board-certified in Internal Medicine by the American Board of Internal Medicine. Formerly, this expert held roles as the Deputy Director of Dermatology and Dental Products and as the Deputy Safety Director for the Division of Metabolism and Endocrinology Products for the US Federal Drug Administration. She also served as an Internist and as the Officer of the Professional Staff at Evanston Northwestern Healthcare. Currently, she serves as the Principal at Amy G Egan Consulting LLC, where she specializes in FDA regulatory matters.
a*********@g*****.com
(301) ***-****
Bonita Springs, Florida
Comprehensive data on expert witnesses: Access detailed litigation history and performance metrics.
Swift assessment: Quickly evaluate an expert's track record.
Informed decisions: Make better choices when selecting or challenging expert witnesses in any case.
Radar Metrics At A Glance
Expert Witness Activity
Plaintiff Cases
Defense Cases
Expert Challenges
Deposition Transcripts
Publications
Media & News
435
Social Media Mentions
Expert Institute operates independently and objectively as an expert witness data provider. Expert Institute does not employ, endorse, or have an affiliation with any expert witnesses for which data is provided.
Expert Witness Activity
Case Name | Role | Filed Date |
|---|---|---|
Gilead Tenofovir Cases | Expert Witness | 2019-09-04 |
Radar monitors both national and state court systems to track litigation activity and access court documents.
View case details, documents, plaintiff and defense representation, defendants, judges, jurisdiction, and more.
Litigation Analytics
Retained By
Defense
Plaintiff
Activity over time
0
25
50
75
100
2000
0
2002
0
2004
0
2006
0
2008
0
2010
0
Activity by state
Case Outcome
0
25
50
75
100
Publications
Title | Type |
|---|---|
Clinical Review of Safety and Efficacy: Division of Metabolism and Endocrinology Products - Rimonabant Briefing Document | Review |
Radar monitors a wide array of publication sources, including links to abstracts.
Review book chapters, journal articles, research papers, trade publications, technical reports, conference proceedings, and more.
Media & News
Radar found 435 records
Title | Description |
|---|---|
lyrglvTyyd - vykypdyh | Mar 11, 2024 -- JAMA Internal Medicine. 173: 534. doi:10.1001 ... Amy G. Egan, M.D., M.P.H., Eberhard Blind, M.D., Ph.D., Kristina Dunder, M.D., Pieter A. |
Lipids and Cardiovascular Risk Management Perspective - Index | Medscape Internal Medicine, August 12, 2011. Simvastatin 80 mg: An FDA Expert Interview Medscape talked to the FDA's Amy Egan, MD, about drug safety ... |
ALXN-1215 - New Drug Approvals | ... Amy G. Egan, M.D., M.P.H., deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research (CDER). "Strensiq's ... |
Radar scours thousands of media and news sources across the internet 24/7.
Access interviews, webinars, TV appearances, blog posts, columns, whitepapers, PDFs, profressional profiles, and more.
Education
Institution | Degree Type |
|---|---|
Johns Hopkins Bloomberg School of Public Health | Master of Public Health |
Loyola University Chicago Stritch School of Medicine | Doctor of Medicine |
Georgetown University School of Medicine | Other |
Work History
Title | Employer |
|---|---|
Principal | Amy G Egan Consulting LLC |
Deputy Director - Office of Drug Evaluation III (“ODE III”) | United States Federal Drug Administration - Center for Drug Evaluation and Research (“CDER”) |
Deputy Director of Safety - Division of Metabolism and Endocrinology Products (“DMEP”) | United States Federal Drug Administration - Center for Drug Evaluation and Research (“CDER”) |
What to expect from a Radar profile
Access detailed litigation history and performance metrics.
Access your Radar profile through Expert iQ, our secure, cloud-based platform that hosts AI-driven insights.
Delivered in 3-5 days
Receive your profile swiftly, with Radar gathering intelligence from thousands of data points.
24/7 monitoring for 12 months
Stay informed with continuous monitoring and live alerts, ensuring your profile is always up-to-date.
